AR038199A1 - Terapia combinada para el tratamiento de infecciones bacterianas - Google Patents
Terapia combinada para el tratamiento de infecciones bacterianasInfo
- Publication number
- AR038199A1 AR038199A1 ARP030100168A ARP030100168A AR038199A1 AR 038199 A1 AR038199 A1 AR 038199A1 AR P030100168 A ARP030100168 A AR P030100168A AR P030100168 A ARP030100168 A AR P030100168A AR 038199 A1 AR038199 A1 AR 038199A1
- Authority
- AR
- Argentina
- Prior art keywords
- aryl
- alkyl
- 3alkyl
- 6alkyl
- hydroxyalkyl
- Prior art date
Links
- 208000035143 Bacterial infection Diseases 0.000 title abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 5
- -1 cyano, carboxyl Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 3
- 125000001188 haloalkyl group Chemical group 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 abstract 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000001769 aryl amino group Chemical group 0.000 abstract 2
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 2
- 125000005110 aryl thio group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000002837 carbocyclic group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 150000003254 radicals Chemical group 0.000 abstract 2
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 1
- 125000004750 (C1-C6) alkylaminosulfonyl group Chemical group 0.000 abstract 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000004749 (C1-C6) haloalkylsulfinyl group Chemical group 0.000 abstract 1
- 125000004741 (C1-C6) haloalkylsulfonyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 abstract 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 abstract 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 125000005354 acylalkyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 abstract 1
- 125000004689 alkyl amino carbonyl alkyl group Chemical group 0.000 abstract 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000006350 alkyl thio alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 125000005018 aryl alkenyl group Chemical group 0.000 abstract 1
- 125000005127 aryl alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 abstract 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 1
- 125000005141 aryl amino sulfonyl group Chemical group 0.000 abstract 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 abstract 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000005164 aryl thioalkyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 229960000590 celecoxib Drugs 0.000 abstract 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004966 cyanoalkyl group Chemical group 0.000 abstract 1
- WAZQAZKAZLXFMK-UHFFFAOYSA-N deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 abstract 1
- 229960003314 deracoxib Drugs 0.000 abstract 1
- 125000004987 dibenzofuryl group Chemical group C1(=CC=CC=2OC3=C(C21)C=CC=C3)* 0.000 abstract 1
- 229960004945 etoricoxib Drugs 0.000 abstract 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 150000004820 halides Chemical class 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005241 heteroarylamino group Chemical group 0.000 abstract 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000005956 isoquinolyl group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 abstract 1
- 125000005493 quinolyl group Chemical group 0.000 abstract 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 abstract 1
- 229960000371 rofecoxib Drugs 0.000 abstract 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- MIMJSJSRRDZIPW-UHFFFAOYSA-N tilmacoxib Chemical compound C=1C=C(S(N)(=O)=O)C(F)=CC=1C=1OC(C)=NC=1C1CCCCC1 MIMJSJSRRDZIPW-UHFFFAOYSA-N 0.000 abstract 1
- 229960002004 valdecoxib Drugs 0.000 abstract 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Proporciona composiciones y métodos para tratar o prevenir las infecciones bacterianas. Las composiciones y métodos incluyen el uso de antibióticos e inhibidores de ciclooxigenasa. Reivindicación 15: El uso de la reivindicación 13, en donde el inhibidor selectivo de la ciclooxigenasa-2 está representado por la fórmula general (1) en donde: A es un anillo heterocíclico parcialmente insaturado, un anillo heterocíclico insaturado, un anillo carbocíclico parcialmente insaturado, o un anillo carbocíclico insaturado; R1 es por lo menos un sustituyente seleccionado entre heterociclilo, cicloalquilo, cicloalquenilo y arilo; en donde R1 está opcionalmente sustituido con uno o más radicales seleccionados entre alquilo, haloalquilo, ciano, carboxilo, alcoxicarbonilo, hidroxilo, hidroxialquilo, haloalcoxilo, amino, alquilamino, arilamino, nitro, alcoxialquilo, alquilsulfinilo, halógeno, alcoxilo y alquiltio; R2 es metilo o amino y R3 es -H, haluro, alquilo, alquenilo, alquinilo, oxo, cianuro, carboxilo, cianoalquilo, heterocicliloxilo, alquiloxilo, alquiltio, alquilcarbonilo, cicloalquilo, arilo, haloalquilo, heterociclilo, cicloalquenilo, arilalquilo, heterociclilalquilo, acilo, alquiltioalquilo, hidroxialquilo, alcoxicarbonilo, arilcarbonilo, arilalquilcarbonilo, arilalquenilo, alcoxialquilo, ariltioalquilo, ariloxialquilo, arialquiltioalquilo, arilalcoxialquilo, alcoxiarilalcoxialquilo, alcoxicarboniloalquilo, aminocarbonilo, aminocarboniloalquilo, alquilaminocarbonilo, N-arilaminocarbonilo, N-alquil-N-arilaminocarbonilo, alquilaminocarbonilalquilo, carboxialquilo, alquilamino, N-arilamino, N-arilalquilamino, N-alquil-N-arilalquilamino, N-alquil-N-arilamino, aminoalquilo, alquilaminoalquilo, N-arilaminoalquilo, N-arilalquilaminoalquilo, N-alquil-N-arilalquilaminoalquilo, N-alquil-N-arilaminoalquilo, ariloxilo, arilalcoxilo, ariltio, arilalquiltio, alquilsulfinilo, alquilsulfonilo, aminosulfonilo, alquilaminosulfonilo, N-arilaminosulfonilo, arilsulfonilo, o N-alquil-N-arilaminosulfonilo. Reivindicación 16: El uso de la reivindicación 13, en donde el inhibidor selectivo de la ciclooxigenasa-2 es celecoxib, valdecoxib, deracoxib, rofecoxib, etoricoxib, JTE-522, o combinaciones de éstos. Reivindicación 23: El uso se la reivindicación 13, en donde el inhibidor selectivo de la ciclooxigenasa-2 es un compuesto de la clase estructural cromeno que tiene la fórmula general (2) en donde: X es O, S, CRcRb o NRa; Ra es -H, C1-3alquilo, fenil-C1-3alquilo, (fenilo sustituido)-C1-3alquilo, C1-3-alcoxicarbonil-C1-3alquilo, o carboxi-C1-6alquilo; Rb y Rc son independientemente -H, C1-3-alquilo, fenil-C1-3alquilo sustituido o no sustituido, C1-3perfluoroalquilo, cloro, C1-6alquiltio, C1-6alcoxilo, nitro, ciano, o ciano-C1-3alquilo; o en donde CRbRc forma un anillo de 3 a 6 miembros; R1 es C1-3-perfluoroalquilo, cloro, C1-6alquiltio, C1-6alcoxilo, nitro, ciano, o ciano-C1-3alquilo; R2 es carboxilo, aminocarbonilo, C1-6alquilsulfonilaminocarbonilo, y C1-6alcoxicarbonilo; R3 es H, fenilo, tienilo, C1-6alquilo, y C2-6alquenilo; en donde R4 es uno o más radicales independientemente seleccionados entre H, halógeno, C1-6alquilo, C2-6alquenilo, C2-6alquinilo , halo-C2-6alquinilo, aril-C1-3alquilo, aril-C2-6alquilo, aril-C2-6alquinilo, aril-C2-6alquenilo, C1-6alcoxilo, metilendioxilo, C1-6alquiltio, C1-6alquilsulfinilo, ariloxilo, ariltio, arilsulfinilo, heteroariloxilo, C1-6alcoxi-C1-6alquilo, aril-C1-6alcoxilo, heteroaril-C1-6alcoxilo, aril-C1-6alcoxi-C1-6alquilo, C1-6haloalquilo, C1-6haloalcoxilo, C1-6haloalquiltio, C1-6haloalquilsulfinilo, C1-6haloalquilsulfonilo, C1-3(haloalquil)-C1-3hidroxialquilo, C1-6hidroxialquilo, hidroxiimino-C1-6alquilo, C1-6alquilamino, arilamino, N-aril-N-C1-6alquilamino, heteroarilamino, N-heteroaril-N-C1-6alquilamino, nitro, ciano, amino, aminosulfonilo, C1-6alquilaminosulfonilo, arilaminosulfonilo, heteroarilaminosulfonilo, N-aril-C1-6alquilaminosulfonilo, N-heteroaril-C1-6alquilaminosulfonilo, heterociclilsulfonilo, C1-6alquilsulfonilo, aril-C1-6alquilsulfonilo, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, aril-C1-6alquilcarbonilo, heteroaril-C1-6alquilcarbonilo, heteroarilcarbonilo, arilcarbonilo, aminocarbonilo, C1-6alcoxicarbonilo, formilo, C1-6haloalquilcarbonilo, o C1-6alquilcarbonilo; o en donde R4 junto con el anillo al cual está unido forma un naftilo, quinolilo, isoquinolilo, quinolizinilo, quinoxalinilo, o dibenzofurilo; y los átomos del anillo A, que son A1, A2, A3, A4, se seleccionan independientemente entre el C y N, con la condición de que por lo menos dos entre A1, A2, A3 y A4 sean carbono.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35105802P | 2002-01-23 | 2002-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038199A1 true AR038199A1 (es) | 2005-01-05 |
Family
ID=27613453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100168A AR038199A1 (es) | 2002-01-23 | 2003-01-21 | Terapia combinada para el tratamiento de infecciones bacterianas |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20030191051A1 (es) |
| EP (1) | EP1467765A2 (es) |
| JP (1) | JP2005517686A (es) |
| KR (1) | KR20040075365A (es) |
| CN (1) | CN1826140A (es) |
| AR (1) | AR038199A1 (es) |
| BR (1) | BR0307085A (es) |
| CA (1) | CA2473254A1 (es) |
| IL (1) | IL162818A0 (es) |
| MX (1) | MXPA04007069A (es) |
| NO (1) | NO20043445L (es) |
| PL (1) | PL371524A1 (es) |
| RU (1) | RU2004122642A (es) |
| TW (1) | TW200403072A (es) |
| WO (1) | WO2003061704A2 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004258745A1 (en) * | 2003-07-31 | 2005-02-03 | Pharmacia & Upjohn Company Llc | Dispersible formulation of an anti-inflammatory agent |
| PT2316419E (pt) * | 2004-05-17 | 2012-10-22 | Gilead Sciences Inc | Combinação de fosfomicina/aminoglicósido em aerossol para o tratamento de infeções respiratórias bacterianas |
| EP1848270B1 (en) | 2005-02-17 | 2014-05-21 | Abbott Laboratories | Transmucosal administration of drug compositions for treating and preventing disorders in animals |
| AR054336A1 (es) * | 2005-03-30 | 2007-06-20 | Astion Dev As | Tratamiento de enfermedades dermatologicas y del prurito |
| BRPI0700969A (pt) | 2007-03-22 | 2008-11-04 | Ouro Fino Participacoes E Empr | composição para o tratamento de afecções bacterianas e inflamatórias em animais de companhia |
| EP2018864A1 (en) | 2007-07-23 | 2009-01-28 | Biomet Deutschland GmbH | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
| MD4009C2 (ro) * | 2008-07-15 | 2010-08-31 | Институт Химии Академии Наук Молдовы | Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos |
| UA92423C2 (ru) * | 2009-07-24 | 2010-10-25 | Анатолій Альбертович Кузьмін | Антибактериальная композиция |
| US9889145B2 (en) * | 2013-04-23 | 2018-02-13 | The Administrators Of The Tulane Educational Fund | Methods to treat infections |
| CN113045498B (zh) * | 2021-03-24 | 2023-01-24 | 江苏食品药品职业技术学院 | 一种1,5-二芳基吡唑衍生物、合成方法及用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9117140D0 (en) * | 1991-08-08 | 1991-09-25 | Unilever Plc | Treatment of periodontitis |
| US5688792A (en) * | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
| US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| EP0892791B1 (en) * | 1996-04-12 | 2003-03-05 | G.D. Searle & Co. | N-[[4-(5-METHYL-3-PHENYLISOXAZOL-4-YL]PHENYL]SULFONYLPROPYLAMIDE and its SODIUMSALT AS PRODRUGS OF COX-2 INHIBITORS |
| GB9615867D0 (en) * | 1996-07-03 | 1996-09-11 | Merck & Co Inc | Process of preparing phenyl heterocycles useful as cox-2 inhibitors |
| US6077850A (en) * | 1997-04-21 | 2000-06-20 | G.D. Searle & Co. | Substituted benzopyran analogs for the treatment of inflammation |
| US6034256A (en) * | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
| WO2000050037A1 (en) * | 1999-02-26 | 2000-08-31 | Nitromed, Inc. | Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use |
| CA2392931A1 (en) * | 1999-12-03 | 2001-06-07 | Pfizer Products Inc. | Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents |
| GB0003685D0 (en) * | 2000-02-17 | 2000-04-05 | Univ Cardiff | Sensitisation of cellular material |
| PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| US20030219461A1 (en) * | 2000-09-12 | 2003-11-27 | Britten Nancy J. | Parenteral combination therapy for infective conditions |
| PE20020578A1 (es) * | 2000-10-10 | 2002-08-14 | Upjohn Co | Una composicion de antibiotico topico para el tratamiento de infecciones oculares |
-
2003
- 2003-01-20 TW TW092101111A patent/TW200403072A/zh unknown
- 2003-01-21 MX MXPA04007069A patent/MXPA04007069A/es not_active Application Discontinuation
- 2003-01-21 CA CA002473254A patent/CA2473254A1/en not_active Abandoned
- 2003-01-21 WO PCT/US2003/000037 patent/WO2003061704A2/en not_active Application Discontinuation
- 2003-01-21 BR BR0307085-9A patent/BR0307085A/pt not_active Application Discontinuation
- 2003-01-21 KR KR10-2004-7011321A patent/KR20040075365A/ko not_active Application Discontinuation
- 2003-01-21 RU RU2004122642/14A patent/RU2004122642A/ru not_active Application Discontinuation
- 2003-01-21 US US10/348,300 patent/US20030191051A1/en not_active Abandoned
- 2003-01-21 CN CNA038026163A patent/CN1826140A/zh active Pending
- 2003-01-21 IL IL16281803A patent/IL162818A0/xx unknown
- 2003-01-21 PL PL03371524A patent/PL371524A1/xx unknown
- 2003-01-21 JP JP2003561646A patent/JP2005517686A/ja active Pending
- 2003-01-21 EP EP03731883A patent/EP1467765A2/en not_active Withdrawn
- 2003-01-21 AR ARP030100168A patent/AR038199A1/es unknown
-
2004
- 2004-08-18 NO NO20043445A patent/NO20043445L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20030191051A1 (en) | 2003-10-09 |
| IL162818A0 (en) | 2005-11-20 |
| CA2473254A1 (en) | 2003-07-31 |
| EP1467765A2 (en) | 2004-10-20 |
| PL371524A1 (en) | 2005-06-27 |
| MXPA04007069A (es) | 2004-11-01 |
| CN1826140A (zh) | 2006-08-30 |
| RU2004122642A (ru) | 2005-03-10 |
| BR0307085A (pt) | 2004-12-07 |
| NO20043445L (no) | 2004-08-18 |
| TW200403072A (en) | 2004-03-01 |
| JP2005517686A (ja) | 2005-06-16 |
| KR20040075365A (ko) | 2004-08-27 |
| WO2003061704A3 (en) | 2003-12-18 |
| WO2003061704A2 (en) | 2003-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038199A1 (es) | Terapia combinada para el tratamiento de infecciones bacterianas | |
| AR064106A1 (es) | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis | |
| EA199800919A1 (ru) | Производные замещенного бензосульфонамида-лекарства ингибиторов сох-2 | |
| JP2011521911A5 (es) | ||
| CY1122949T1 (el) | ΠΥΡΑΖΟΛΟ[1,5-a]ΠΥΡΑΖΙΝ-4-ΥΛΟ ΠΑΡΑΓΩΓΑ ΩΣ JAK-ΑΝΑΣΤΟΛΕΙΣ | |
| RU2435760C2 (ru) | 1н-хиназолин-2,4-дионы | |
| NZ509755A (en) | Method of using benzenesulphoamides that are cyclooxygenase-2-inhibitors in the treatment and prevention of neoplasia | |
| CA2217455A1 (fr) | Nouveaux derives substitues, de biphenyle ou de phenylpiridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| EA202190116A1 (ru) | Агент для профилактики или лечения спинальной мышечной атрофии | |
| RU2487124C2 (ru) | Новое амидное производное и его использование в качестве лекарственного средства | |
| AR080134A1 (es) | Ligandos sigma para la prevencion y/o el tratamiento del dolor postoperatorio | |
| AR047537A1 (es) | Piridazinonaureas como antagonistas de integrinas | |
| AR054612A1 (es) | Derivados de espiroquetas y composiciones farmaceuticas para su utilizacion como agente terapeutico para diabetes | |
| AR063653A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR040076A1 (es) | Derivados de piridazin-3(2h)-ona | |
| RU2009146008A (ru) | Синергическая фармацевтическая комбинация для лечения рака | |
| AR052319A1 (es) | Compuestos biciclicos sustituidos por sulfonilo en funcion de moduladores del ppar | |
| KR927003052A (ko) | 2-아릴티아졸 유도체 및 그의 약제학적 조성물 | |
| BR112018074632A2 (pt) | combinações compreendendo inibidores de histona desacetilase | |
| AR077876A1 (es) | Ligandos del receptor sigma para la prevencion o el tratamiento de dolor inducido por quimioterapia | |
| AR039189A1 (es) | Compuesto de pirrolopiridazina, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
| CA2693180A1 (en) | Fused bicyclic compound | |
| AR058406A1 (es) | Antagonistas del receptor de proquineticina 1 | |
| AR086636A1 (es) | Ligandos sigma utiles para tratar y/o prevenir el dolor asociado a la diabetes tipo 2 y composiciones farmaceuticas que los contienen | |
| AR054083A1 (es) | Compuestos imidazol y su utilizacion paar preparar medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |